© 2020 John Wiley & Sons Ltd.Novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome virus (SARS-CoV-2) has become a global healthcare crisis. The Centers for Disease Control and Prevention (CDC) lists immunocompromised patients, including those requiring immunosuppression following renal transplantation, as high-risk for severe disease from SARS-CoV-2. Treatment for other viral infections in renal transplant recipients often includes a reduction in immunosuppression, however, there are no current guidelines recommending the optimal approach to managing immunosuppression in the patients who are infected with SARS-CoV-2. It is currently recommended to avoid corticosteroids in the treatment of SARS-CoV-2 outside of critically ill patients. Recently published cases describing the inpatient care of COVID-19 in renal transplant recipients differ widely in disease severity, time from transplantation, baseline immunosuppressive therapy, and the modifications made to immunosuppression during COVID-19 treatment. The purpose of this review is to summarize and compare inpatient immunosuppressant management strategies of recently published reports in the renal transplant population infected with SARS-CoV-2 and to discuss the limitations of corticosteroids in managing immunosuppression in this patient population. This article is protected by copyright. All rights reserved.Correction of calculation errors in the original article led to the change of bead type for the unprotonated beads in the coarse-grained polyethylenimine model. The original model was still of good quality while the updated model showed better performance in describing the interaction between polyethylenimine and DNA. © 2020 Wiley Periodicals, Inc.The European Academy of Allergy and Clinical Immunology (EAACI) is the leading organisation in the field of Allergy, Asthma and Clinical Immunology with nearly 12,000 members from 124 countries and works with over 70National Allergy Societies. It is the primary source of expertise in Europe and worldwide for all aspects of allergic diseases and asthma. Recent efforts by EAACI resulted in a successful Strategic Forum on Allergic Diseases (1), with key opinion leaders acknowledging the impact of translational research in cultivating multidirectional and multidisciplinary integration of basic research as well as patient-oriented, population-based studies, with the long-term objective of improving the management of allergic diseases and asthma. This article is protected by copyright. All rights reserved.BACKGROUND A single, simplified approach for human immunodeficiency virus (HIV)-1/HIV-2 antibody confirmation/differentiation is needed for the HIV blood donation supplemental algorithm used in the United States. A clinical evaluation of the Geenius assay was performed-the same assay used for HIV diagnostic confirmation/differentiation in the United States since 2014. STUDY DESIGN AND METHODS Well-characterized unlinked donation samples classified as HIV negative, false positive, or confirmed positive were included in the study 200 antibody-nonreactive, 200 HIV-1 immunofluorescence assay (IFA) confirmed-positive, and 100 antibody-screen false-positive donations, equally divided between serum and plasma. Samples were retrieved from a repository, relabeled, and tested by an immunochromatographic test (Geenius HIV 1/2 Supplemental Assay, Bio-Rad). Comparator testing involved parallel US Food and Drug Administration (FDA)-licensed HIV-1 IFA or HIV-2 enzyme immunoassay (EIA) supplemental testing for any sample mis-EIA tests. © 2020 AABB.PURPOSE Motion compensated positron emission tomography (PET) imaging requires detecting and monitoring of patient body motion. We developed a semiautomatic list-mode method to track the three-dimensional (3D) motion of fiducial positron-emitting markers during PET imaging. METHODS A previously developed motion tracking method using positron-emitting markers (PeTrack) was enhanced to work with PET imaging. A novel combination of filtering methods was developed to reject physiological tracer background, which would drown out the events from the marker if unfiltered. The most critical filter rejects events whose line-of-response (LOR) is outside an adaptive region of interest (ADROI). The size of ROI was optimized by exploiting the distinct differences between the distributions of events from background and marker. The ADROI PeTrack method was evaluated with Monte Carlo and phantom studies. A 92.5-kBq 22 Na marker moving sinusoidally in 3D was simulated with Monte Carlo methods. The simulated events were combinthm and background rejection methods were developed that can track the 3D motion of low-activity positron-emitting markers during PET imaging. The motion information may be used for motion-compensated PET imaging. This article is protected by copyright. All rights reserved.BACKGROUND The aim of this study was to understand Australian donors' and nondonors' orientations toward 13 noncash incentives for blood and plasma donation and the associations between orientations and intention to donate (nondonors) and subsequent donation (donors). STUDY DESIGN AND METHODS A survey of 1028 donors and 1201 nondonors was conducted online and by telephone. Donors were randomly selected from the Australian Red Cross Lifeblood donor panel; nondonors were selected from randomly generated fixed line and mobile telephone numbers across Australia. https://www.selleckchem.com/products/skf-34288-hydrochloride.html Incentives were chosen to reflect a wide array of possible noncash incentives that might be introduced by blood donation organizations (BDOs). Differences between donors and nondonors, as well as other subgroups, were investigated. RESULTS Orientations toward most types of incentives were positive or neutral. No significant differences were observed between incentive orientations for whole blood versus plasma donations. Many subgroup differences were small but statistically significant. There were mostly small, positive, significant associations between nondonors' intention to donate and orientations toward noncash incentives; there were mostly no significant associations between donors' orientations and subsequent donation behaviors. CONCLUSION The findings from this study suggest that BDOs that wish to trial noncash incentives in voluntary nonremunerative systems can be confident that neither donors nor potential donors will react negatively. They also indicate that BDOs have some flexibility in deciding which incentives to trial. © 2020 AABB.